FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085277577> ?p ?o ?g. }

• W2085277577 endingPage "656" @default.
• W2085277577 startingPage "649" @default.
• W2085277577 abstract "Autologous hematopoietic stem cell transplantation (autoSCT) is an effective treatment for patients with various hematologic malignancies. Despite the significant improvement in the overall outcome, disease progression after transplantation remains the major cause of treatment failure. With longer follow-up, therapy-related myelodysplasia/acute myelogenous leukemia is becoming an important cause of treatment failure. The prognosis for these 2 groups of patients is very poor. Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potential curative treatment for these patients. However, the outcome with conventional myeloablative alloSCT after failed autoSCT is typically poor because of high transplant-related mortality. In an attempt to reduce the treatment-related toxicity, we studied a reduced-intensity conditioning regimen followed by alloSCT for patients with progressive disease or therapy-related myelodysplasia/acute myelogenous leukemia after autoSCT. This report describes the outcomes of 28 patients with hematologic malignancies who received a reduced-intensity alloSCT after having treatment failure with a conventional autoSCT. Fourteen patients received a hematopoietic stem cell transplant from a related donor and 14 from an unrelated donor. The conditioning regimen consisted of low-dose (2 Gy) total body irradiation with or without fludarabine in 4 patients and the combination of melphalan (140 mg/m(2)) and fludarabine in 24. Cyclosporine and mycophenolate mofetil were used for posttransplantation immunosuppressive therapy, as well as graft-versus-host disease (GVHD) prophylaxis, in all patients. All patients engrafted and had >90% donor chimerism on day 100 after SCT. Currently, 13 patients (46%) are alive and disease free, 7 patients (25%) developed disease progression after alloSCT, and 8 (32%) died of nonrelapse causes. Day 100 mortality and nonrelapse mortality were 25% and 21%, respectively. With a median follow-up of 24 months for surviving patients, the 2-year probabilities of overall survival, event-free survival, and relapse rates were 56.5%, 41%, and 41.9%, respectively. Six patients (21%) developed grade III to IV acute GVHD. Among 21 evaluable patients, 15 (67%) developed chronic GVHD. We conclude that (1) reduced-intensity alloSCT is feasible and has an acceptable toxicity profile in patients who have previously received autoSCT and that (2) although follow-up was short, a durable remission may be achieved in some patients who would otherwise be expected to have a poor outcome." @default.
• W2085277577 created "2016-06-24" @default.
• W2085277577 creator A5004358801 @default.
• W2085277577 creator A5011178245 @default.
• W2085277577 creator A5011455409 @default.
• W2085277577 creator A5019419203 @default.
• W2085277577 creator A5020684790 @default.
• W2085277577 creator A5023917993 @default.
• W2085277577 creator A5025887498 @default.
• W2085277577 creator A5027155042 @default.
• W2085277577 creator A5034400547 @default.
• W2085277577 creator A5035985145 @default.
• W2085277577 creator A5039374832 @default.
• W2085277577 creator A5046784402 @default.
• W2085277577 creator A5052032114 @default.
• W2085277577 creator A5058365130 @default.
• W2085277577 creator A5062110857 @default.
• W2085277577 creator A5065361845 @default.
• W2085277577 creator A5074606840 @default.
• W2085277577 creator A5075376684 @default.
• W2085277577 creator A5075930791 @default.
• W2085277577 creator A5083260440 @default.
• W2085277577 creator A5086123605 @default.
• W2085277577 creator A5091818686 @default.
• W2085277577 date "2003-10-01" @default.
• W2085277577 modified "2023-10-17" @default.
• W2085277577 title "Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed" @default.
• W2085277577 cites W1479909146 @default.
• W2085277577 cites W1497143314 @default.
• W2085277577 cites W1530764705 @default.
• W2085277577 cites W1873141201 @default.
• W2085277577 cites W1990045245 @default.
• W2085277577 cites W2010713505 @default.
• W2085277577 cites W2021152594 @default.
• W2085277577 cites W2034519717 @default.
• W2085277577 cites W2071531342 @default.
• W2085277577 cites W2093369626 @default.
• W2085277577 cites W2131706663 @default.
• W2085277577 cites W2158211462 @default.
• W2085277577 cites W2322774633 @default.
• W2085277577 cites W2327134323 @default.
• W2085277577 cites W2337680764 @default.
• W2085277577 cites W2467788979 @default.
• W2085277577 cites W2473437262 @default.
• W2085277577 cites W4246085869 @default.
• W2085277577 doi "https://doi.org/10.1016/s1083-8791(03)00241-6" @default.
• W2085277577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14569561" @default.
• W2085277577 hasPublicationYear "2003" @default.
• W2085277577 type Work @default.
• W2085277577 sameAs 2085277577 @default.
• W2085277577 citedByCount "23" @default.
• W2085277577 countsByYear W20852775772012 @default.
• W2085277577 countsByYear W20852775772013 @default.
• W2085277577 countsByYear W20852775772015 @default.
• W2085277577 countsByYear W20852775772018 @default.
• W2085277577 countsByYear W20852775772020 @default.
• W2085277577 crossrefType "journal-article" @default.
• W2085277577 hasAuthorship W2085277577A5004358801 @default.
• W2085277577 hasAuthorship W2085277577A5011178245 @default.
• W2085277577 hasAuthorship W2085277577A5011455409 @default.
• W2085277577 hasAuthorship W2085277577A5019419203 @default.
• W2085277577 hasAuthorship W2085277577A5020684790 @default.
• W2085277577 hasAuthorship W2085277577A5023917993 @default.
• W2085277577 hasAuthorship W2085277577A5025887498 @default.
• W2085277577 hasAuthorship W2085277577A5027155042 @default.
• W2085277577 hasAuthorship W2085277577A5034400547 @default.
• W2085277577 hasAuthorship W2085277577A5035985145 @default.
• W2085277577 hasAuthorship W2085277577A5039374832 @default.
• W2085277577 hasAuthorship W2085277577A5046784402 @default.
• W2085277577 hasAuthorship W2085277577A5052032114 @default.
• W2085277577 hasAuthorship W2085277577A5058365130 @default.
• W2085277577 hasAuthorship W2085277577A5062110857 @default.
• W2085277577 hasAuthorship W2085277577A5065361845 @default.
• W2085277577 hasAuthorship W2085277577A5074606840 @default.
• W2085277577 hasAuthorship W2085277577A5075376684 @default.
• W2085277577 hasAuthorship W2085277577A5075930791 @default.
• W2085277577 hasAuthorship W2085277577A5083260440 @default.
• W2085277577 hasAuthorship W2085277577A5086123605 @default.
• W2085277577 hasAuthorship W2085277577A5091818686 @default.
• W2085277577 hasBestOaLocation W20852775771 @default.
• W2085277577 hasConcept C126322002 @default.
• W2085277577 hasConcept C141071460 @default.
• W2085277577 hasConcept C143998085 @default.
• W2085277577 hasConcept C2776694085 @default.
• W2085277577 hasConcept C2776755627 @default.
• W2085277577 hasConcept C2777408962 @default.
• W2085277577 hasConcept C2778684742 @default.
• W2085277577 hasConcept C2778880498 @default.
• W2085277577 hasConcept C2779050716 @default.
• W2085277577 hasConcept C2779263901 @default.
• W2085277577 hasConcept C28328180 @default.
• W2085277577 hasConcept C2911091166 @default.
• W2085277577 hasConcept C54355233 @default.
• W2085277577 hasConcept C71924100 @default.
• W2085277577 hasConcept C86803240 @default.
• W2085277577 hasConceptScore W2085277577C126322002 @default.
• W2085277577 hasConceptScore W2085277577C141071460 @default.
• W2085277577 hasConceptScore W2085277577C143998085 @default.

• next